; (B) the co-occurrence of pregnancy and substance use disorder; (C) the clinical guidance about treating substance use disorder in pregnant and post­par­tum women; and (D) appropriate screening and interventions for infants affected by substance use disorder, withdrawal symptoms, or a fetal alcohol spectrum disorder and the requirements under section 106(b)(2)(B)(iii). (4) Establishing partnerships, agreements, or memoranda of understanding between the lead agency and health professionals, health facilities, child welfare professionals, substance use disorder and mental health disorder treatment programs, and maternal and child health and early intervention professionals, including home visiting providers, peer recovery specialists, and housing agencies to facilitate the implementation of, and compliance with section 106(b)(2) and paragraph (2) of this subsection, in areas which may include— (A) developing a comprehensive, multi-disciplinary assessment and intervention process for infants and their families who are affected by substance use disorder, withdrawal symptoms, or a fetal alcohol spectrum disorder, that takes into account the unique needs of each family and addresses differences between legal, medically supervised substance use, and substance use disorder; (B) ensuring that treatment approaches for serving infants, pregnant women, and perinatal and postnatal women whose infants may be affected by substance use, withdrawal symptoms, or a fetal alcohol spectrum disorder, are designed to, where appropriate, keep infants with their mothers during both inpatient and outpatient treatment